City Therapeutics (NASDAQ:CTY) Stock Jumps 6.7% – Time to Buy?

City Therapeutics, Inc. (NASDAQ:CTY – Get Free Report) rose 6.7% on Thursday. The stock traded as high as $18.06 and last traded at $17.75. 111,764 shares were traded during trading, a decline of 60% from the average daily volume of 281,349 shares. The stock had previously closed at $16.64.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CTY. Zacks Research initiated coverage on shares of City Therapeutics in a research report on Wednesday, November 11th. They set a “hold” rating on the stock. Oppenheimer assumed coverage on City Therapeutics in a research report on Tuesday, November 10th. They issued an “outperform” rating and a $46.00 target price for the company. Wall Street Zen raised City Therapeutics to a “hold” rating in a research note on Saturday, October 24th. Stifel Nicolaus initiated coverage on City Therapeutics in a report on Tuesday, November 10th. They issued a “buy” rating and a $34.00 price target on the stock. Finally, Jefferies Financial Group began coverage on City Therapeutics in a research note on Monday, November 16th. They issued a “strong-buy” rating for the company. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $37.33.

View Our Latest Report on CTY

City Therapeutics Stock Up 5.3%

Insider Buying and Selling

In other news, Director Robert Nelsen acquired 170,000 shares of the business’s stock in a transaction dated Monday, October 19th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $3,060,000.00. Following the acquisition, the director owned 13,692,507 shares of the company’s stock, valued at $246,465,126. This trade represents a 1.26% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Arch Venture Partners Xii, Llc acquired 170,000 shares of the business’s stock in a transaction dated Monday, October 19th. The stock was purchased at an average price of $18.00 per share, with a total value of $3,060,000.00. Following the completion of the acquisition, the insider directly owned 13,692,507 shares in the company, valued at approximately $246,465,126. This represents a 1.26% increase in their position. The disclosure for this purchase is available in the SEC filing.

City Therapeutics Company Profile

(Get Free Report)

City Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-related proteins. Its research focuses on designing RNAi therapies for potential use across a range of diseases. Launched in 2024, the company is developing technology intended to advance the design and delivery of RNAi medicines. Its work is research and development focused; the company’s activities center on building a therapeutic pipeline rather than marketing established products.

Further Reading

Receive News & Ratings for City Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for City Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.